In this episode, Dennis Walker and Mikaela de la Myco dive into the intersection of sex and psychedelics and discuss her experiences with sacred intimacy, indigenous Mexican ceremony, and womb care facilitation.
In this episode, Sacha sits down with Stephanie Wang, the founder of KA! Empathogenics. They get into the exciting benefits Kanna, sometimes dubbed as ‘Nature’s MDMA’.
Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founder & CEO, of Mydecine Innovations Group, Josh Bartch.
In this episode, David Flores speaks with Matt Zemon, the co-founder of Happy and author of Psychedelic for Everyone. They open up about deeply personal stories about their childhood, with Matt sharing a beautiful story about connecting with his son Cole.
Two doses of psilocybin over a period of eight weeks significantly reduced alcohol use and cravings for alcoholics. That’s according to early results of a New York University phase 2 study.
Mydecine (OTC: MYCOF, NEO: MYCO) is an aspiring psychedelics medicine company that aims to use psilocybin, the active ingredient in magic mushrooms, to treat smoking addiction and PTSD. First, they are using pure psilocybin called MYCO-001, but eventually, Mydecine wants to use a proprietary, shorter-lasting compound called MYCO-004.
While Mydecine probably isn’t considered as being in the top tier of psychedelic researchers (yet at least), they recently have teamed up with Johns Hopkins University and Dr. Matthew Johnson, an institution and individual widely considered to be leaders in the field. With this partnership, Mydecine may become a leader among the “shroom stocks”.
Specifically, Mydecine and Johns Hopkins are joining forces to run phase 2 and 3 clinical trials treating smoking addiction with psilocybin, though they may expand their partnership in the future.
Is Mydecine (MYCO:NEO) (MYCOF: OTC ) one of the best penny stocks of 2021? Can magic mushrooms treat smoking addiction? Watch the episode to find out!
Waht do you guys think about the Mydecine partnering up with Johns Hopkins University?
Links:
https://uploads-ssl.webflow.com/5ee12ebc38f9e96f52217dd1/610efbd58b2b1755e49eb55b_MYCO_Presentation_8.6.21-compressed.pdf
https://www.hopkinsmedicine.org/profiles/details/matthew-johnson
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MYDECINE #MYCO #JOHNSHOPKINS
Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain…
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
